SWI Initiates Coverage on Hemispherx Biopharma, Inc. Download Research Report – Watch CEO Interview
Marina del Rey, CA – August 3, 2016 – SWI today announced that it has initiated coverage on Hemispherx Biopharma, Inc. (NYSE:HEB). HEB is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection®, the experimental therapeutics Ampligen® and Alferon® LDO.
Hemispherx Biopharma, Inc. is a company that has implemented a structure with promising products pron for extraordinary success in place. We consider HEB an exceptional investment opportunity that you cannot afford to miss.